Baxter Issues Updated Use Instructions for Volara Ventilator Circuits Following Serious Injury Reports
Baxter International has issued an Urgent Medical Device Correction for its Volara respiratory therapy system, specifically involving single-patient use circuits (Blue Ventilator Adaptor Module, Product Code M07937) used in conjunction with ventilators.
The U.S. Food and Drug Administration has classified this action as a Class I recall, the most serious type, indicating that continued use without adherence to updated instructions may cause serious injury or death.
Importantly, this is a field correction, not a product removal. Devices remain in use, but updated Instructions for Use (IFU) must be followed.
What Changed
Baxter updated use instructions for all affected Volara circuits after identifying risks associated with in-line use with ventilators in home care settings. The correction includes an updated IFU addendum, additional warnings for patient populations, reinforced monitoring requirements, and required training and acknowledgment by users.
Risk Overview
Baxter identified two primary risks when the Volara system is used in-line with a ventilator. The risks are oxygen desaturation (reduced oxygen levels) and barotrauma (lung injury from overexpansion).
These risks arise because the Volara system introduces additional flow and pressure, which may interfere with ventilator performance and therapy accuracy.
Reported Events
Seven serious injuries were reported between May 2022 and March 2026. No deaths were reported in this updated correction. Prior reporting for events in 2022 included one serious injury and two deaths.
Required Actions for Patients and Caregivers
Patients using the Volara system in-line with a ventilator should continue therapy as prescribed by their physician and carefully review the updated IFU addendum. Patients and caregivers should also monitor for signs of respiratory distress, including an increased breathing rate, wheezing, a bluish discoloration of the lips or nails, reduced oxygen saturation, or changes in alertness.
If symptoms occur, stop therapy immediately and seek medical attention if symptoms do not improve.
Additional Safeguards
Baxter is implementing direct communication with all affected users, access to 24/7 clinical support, in-home training by clinical patient trainers, and confirmation of understanding of updated instructions.
Regulatory Insight (MDP Perspective)
This correction highlights several critical regulatory and quality system themes.
System Integration Risk
Combining devices (Volara + ventilator) introduces complex interactions not always fully predictable during initial design.
Importance of IFU Clarity
In home care environments, instructions must account for non-clinical users (patients/caregivers).
Post-Market Surveillance
This issue underscores how real-world use reveals risks that may not emerge during premarket evaluation.
Training as a Risk Control
The requirement for IFU acknowledgment that includes in-home training demonstrates that user behavior is a critical control point.
Bottom Line
The Volara correction is a strong example of how device performance, user interaction, and system integration must be continuously evaluated in real-world conditions. For manufacturers, this reinforces the need for robust risk management, clear labeling and instructions, and effective post-market monitoring.
Contact Information
U.S. customers with questions should contact Baxter at 800-397-9071 for clinical support.
Links
Read the FDA’s announcement here.
One Contaminated Alcohol Pad, Multiple Recalls
A Lesson in Medical Device Supply Chain Quality At first glance, Cardinal Health's recent recall of Webcol™ Alcohol Prep Pads appears straightforward. A commonly used healthcare product was found to be contaminated with Paenibacillus phoenicis, creating a potential...
Early Alert: Windstone Medical Recall for Convenience Kits
FDA Warns of Convenience Kits Containing Recalled Cardinal Health Alcohol Pads The FDA has issued an Early Alert regarding several medical convenience kits distributed by Windstone Medical Packaging, Inc. that contain alcohol prep pads previously recalled by Cardinal...
Webcol Alcohol Prep Pads Recall Due to Microbial Contamination
Cardinal Health Recalls Alcohol Prep Pads Over Infection Risk Concerns Cardinal Health has issued a voluntary nationwide recall of select lots of its Webcol™ Large Alcohol Prep Pads (70% isopropyl alcohol) after testing identified microbial contamination with...
FDA Issues Warning Letter for Modifications to Infant Products
FDA Issues Warning Letter to Happiest Baby Over SNOO Smart Sleeper Modifications and Quality System Deficiencies The U.S. Food and Drug Administration has issued a Warning Letter to Happiest Baby, Inc., manufacturer of the SNOO Smart Sleeper, citing unapproved device...
FDA Expands Draeger Atlan Anesthesia Workstation Correction
More anesthesia machines added to correction for potential ventilation failure The U.S. Food and Drug Administration (FDA) has designated a recent expansion of Draeger, Inc.'s Atlan anesthesia workstation correction as a Class I recall, the agency's most serious...
Warning Letter to Zoll Medical for Major QMS Violations
Warning Letter to Zoll Medical for Major QMS Violations The U.S. Food and Drug Administration has issued a Warning Letter to ZOLL Medical Corporation citing significant Quality System Regulation (QSR) violations involving corrective and preventive action (CAPA),...